Izolda Rosario
Gerontology · Elmhurst, ILNPI 1083222368
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Urovant Sciences Inc accounts for 78.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $225 and has fallen 92.7% since, to $16 in 2025.
Across 39 payments — averaging $13.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urovant Sciences Inc$420
- Mylan Specialty L.p.$74
- Neurocrine Biosciences, Inc.$26
- Viatris Specialty LLC$16
What the payments were for
- Food & beverage$536100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urovant Sciences Inc | 34 | $420 |
| Mylan Specialty L.p. | 3 | $74 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Viatris Specialty LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEMTESA$125
How this compares
$536 in reported general payments places this provider in the 65th percentile of 180 gerontology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 157 | $38,827 |
| OzempicSemaglutide | 20 | $21,726 |
| EliquisApixaban | 50 | $15,577 |
| TrulicityDulaglutide | 14 | $13,921 |
| MyrbetriqMirabegron | 24 | $5,563 |
| XareltoRivaroxaban | 19 | $5,404 |
| Potassium Chloride | 110 | $3,563 |
| Bumetanide | 36 | $1,928 |
| Levothyroxine Sodium | 80 | $1,052 |
| VascepaIcosapent Ethyl | 21 | $980 |
| Gabapentin | 51 | $973 |
| Baclofen | 29 | $822 |
| Levetiracetam | 29 | $717 |
| Tamsulosin Hcl | 43 | $665 |
| MethotrexateMethotrexate Sodium | 11 | $664 |
Paid to pharmacies, not to this prescriber.
Other gerontology in Elmhurst
- Brynn O DonnellElmhurst$1K
- Joseph StokesChicago$16K
- Stephanie VerderameRockford$15K
- Megan BonisNiles$15K
- Cheryl RogersKankakee$15K
- June LosurdoHinsdale$9K
- Hayley MillsMoline$7K
- Carlyn NewellOlympia Fields$7K
- Ann WaldronMatteson$6K
- Kristin RyanArlington Heights$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.